Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 9/20 | 0.54 |
| ▸ | MAPT | P10636 | 5/20 | 0.54 |
| ▸ | MEN1 | O00255 | 4/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | NSD2 | O96028 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | TTR | P02766 | 1/20 | 0.50 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | F2 | P00734 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7074980 | 0.89 | KMT2A (0.47) | KMT2AMAPTMEN1TDP1NSD2 | |
| SCHEMBL7634289 | 0.88 | KMT2A (0.46) | KMT2AMAPTMEN1TDP1NSD2 | |
| SCHEMBL11124466 | 0.86 | NSD2 (0.69) | KMT2AMAPTMEN1TDP1NSD2 | |
| SCHEMBL11511170 | 0.86 | KMT2A (0.54) | KMT2AMAPTMEN1TDP1NSD2 | |
| SCHEMBL28940650 | 0.84 | KMT2A (0.54) | KMT2AMAPTMEN1TDP1NSD2 | |
| SCHEMBL11999789 | 0.84 | KMT2A (0.53) | KMT2AMAPTMEN1TDP1NSD2 | |
| SCHEMBL27490485 | 0.83 | TTR (0.52) | KMT2AMAPTMEN1TTRGAA | |
| SCHEMBL7711402 | 0.83 | KMT2A (0.60) | KMT2AMAPTMEN1TDP1NSD2 | |
| SCHEMBL2755026 | 0.82 | KMT2A (0.68) | KMT2AMAPTMEN1TDP1NSD2 | |
| SCHEMBL11072007 | 0.82 | KMT2A (0.64) | KMT2AMAPTMEN1TDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101044432-B | Alkali development-type photosensitive resin composition, substrate with projections for liquid crystal division alignment control formed using the same, and liquid crystal display device | TOPPAN PRINTING CO.,LTD. (JP) | 2011-12-14 | — | — | CN | disclosed |
| CN-101044432-A | Alkali development-type photosensitive resin composition, substrate with projections for liquid crystal division alignment control formed using the same, and liquid crystal display device | TOPPAN PRINTING CO LTD (JP) | 2007-09-26 | — | — | CN | disclosed |
| US-6358515-B2 | ANTIHYPERTENSIVE PHARMACEUTICAL COMPOSITION; TREATMENT OF GLAUCOMA | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2002-03-19 | — | — | US | disclosed |
| US-20010008893-A1 | HYDROQUINONE DERIVATIVES | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2001-07-19 | — | — | US | disclosed |
| EP-0972766-A1 | HYDROQUINONE DERIVATIVES | Senju Pharmaceutical Co., Ltd. (JP) | 2000-01-19 | — | — | EP | disclosed |
| US-5393776-A | Tocotrienol analogs in the treatment of hypercholesterolemia and hyperlipidemia | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-02-28 | — | — | US | disclosed |
| EP-0571928-A1 | Acyclic Tocotrienol analogs in the treatment of hypercholesterolemia and hyperlipidemia | Bristol-Myers Squibb Company (US) | 1993-12-01 | — | — | EP | disclosed |
| EP-0476493-A1 | Acyclic tocotrienol analogs in the treatment of hypercholesterolemia and hyperlipidemia | Bristol-Myers Squibb Company (US) | 1992-03-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010008893-A1 | HYDROQUINONE DERIVATIVES | REN, AGTR1, AGTR2 | KMT2A 2128/4885MAPT 4729/4885MEN1 2775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.